FDA Accepts Application for Adjuvant Pembrolizumab for Stage III Melanoma
The FDA has accepted a supplemental biologics license application for the use of pembrolizumab as an adjuvant treatment for patients with resected, high-risk stage III melanoma.
Source: OncLive